HistoIndex returned to the AASLD Annual Meeting, hosting a highly engaging Breakfast Reception in San Diego, California.  

Attended by leading hepatologists, researchers, and industry professionals, the session showcased the latest advancements in fibrosis assessment and MASH (Metabolic Associated Steatohepatitis) management. 

The discussions highlighted the transformative role of SHG (Second Harmonic Generation) imaging and AI-driven analytics in delivering earlier treatment insights, personalized care, and improved clinical outcomes. Cutting-edge innovations like qFibrosis® and FibroSIGHT™ underscored HistoIndex’s leadership in redefining liver disease management.

Key Highlights from the session

• qFibrosis for Early Detection: AI-enabled qFibrosis demonstrated superior sensitivity in capturing fibrosis improvements at early stages (Week 24) compared to traditional pathologist assessments, making it a critical tool for tracking treatment efficacy in MASH.

• Clinical Utility of SHG Imaging: SHG imaging significantly enhances visualization and quantification of fibrosis, improving pathologist concordance and offering precise staging, particularly for challenging lower-stage fibrosis cases.

• Predicting Long-Term Outcomes: The integration of SHG and AI-based methodologies with NASH-CRN cohort data offers promising pathways to predict clinical outcomes, aiding in the development of personalized treatment strategies.

• FibroSIGHT™ Introduction: A new laboratory-developed test (LDT), FibroSIGHT™, utilizes SHG imaging and AI to generate comprehensive fibrosis assessments and risk stratifications, empowering clinicians to make informed decisions. Stay tuned for more exciting updates on this innovative offering from HistoIndex.

• Roundtable Discussions: Experts explored how advancements like qFibrosis and SHG imaging can be integrated into routine clinical practice to enhance patient outcomes and accelerate drug development in liver diseases.

We look forward to the next meeting. To learn more contact us.